Trial · NCT05422885

Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

NCT05422885, Phase 1, Phase 2, Completed, Lewis Lipsitz; results first posted 2025-03-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease. Trials, record NCT05422885. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05422885

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
NCT number: NCT05422885
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 15 participants, actual
Lead sponsor: Lewis Lipsitz
Conditions: Aging
Interventions: Dasatinib, Quercetin
First posted: 2022-06-21
Last updated: 2025-03-17
Results first posted: 2025-03-17
Limitations and caveats: Although we collected urine samples, the SASP factors (i.e., biomarkers) we were not measured due to insufficient funds and resources. Therefore, we are unable to analyze any data.

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Neurovascular Coupling	Screening, 8, and 14 weeks	Change in cerebral blood flow during an N-back cognitive task using transcranial doppler ultrasound.
Primary	Executive Function	Baseline, 8, and 14 weeks	Assess change in executive cognitive function using TRAILS test, corrected for response time. Higher scores indicate worse executive functioning.
Primary	Gait Speed	Baseline, 8, and 14 weeks	Assess change in gait speed. Performed without a distracting cognitive task.
Primary	Montreal Cognitive Assessment (MoCA) Score	Baseline, 8, and 14 weeks	The Montreal Cognitive Assessment evaluates global cognition. Scores range from 0-30 points, with higher scores indicating better cognition
Secondary	Physical Performance	Baseline, 8, and 14 weeks	Assessment of overall physical function using the short physical performance battery (SPPB) scored from 0-12, based on a composite of balance, strength, and walking speed. Higher scores indicate better mobility.
Secondary	Mobility	Baseline, 8, and 14 weeks	Test of mobility using timed up and go test, including standing from a chair, walking, and turning.
Secondary	Grip Strength	Baseline, 8, and 14 weeks	Measure of grip strength using a hand dynamometer.
Secondary	Gait Speed During Cognitive Task	Baseline, 8, and 14 weeks	Measure of gait speed during a cognitive task.
Secondary	P16 ink4a Expression in CD3 Positive Cells	Screening and 14 weeks	Measure of P16 ink4a expression in senescent CD3 lymphocytes in the blood.
Secondary	SASP Factors in Blood and Urine	Screening and 14 weeks	Measure of the senescence-associated biomarkers IL-1alpha picogram/mL and IL-6 picogram/mL.

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Neurovascular Coupling	Screening, 8, and 14 weeks	cm/s	MEAN
PRIMARY	Executive Function	Baseline, 8, and 14 weeks	seconds	MEAN
PRIMARY	Gait Speed	Baseline, 8, and 14 weeks	meters/second	MEAN
PRIMARY	Montreal Cognitive Assessment (MoCA) Score	Baseline, 8, and 14 weeks	points	MEAN
SECONDARY	Physical Performance	Baseline, 8, and 14 weeks	points	MEAN
SECONDARY	Mobility	Baseline, 8, and 14 weeks	seconds	MEAN
SECONDARY	Grip Strength	Baseline, 8, and 14 weeks	kilograms	MEAN
SECONDARY	Gait Speed During Cognitive Task	Baseline, 8, and 14 weeks	meters/second	MEAN
SECONDARY	P16 ink4a Expression in CD3 Positive Cells	Screening and 14 weeks	relative expression to housekeeping gene	MEAN
SECONDARY	SASP Factors in Blood and Urine	Screening and 14 weeks	picograms/mL	MEAN

1 to 10 of 11Source ClinicalTrials.gov

See all 11 outcomes

Results by group32

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Neurovascular Coupling	Dasatinib and Quercetin	Screening	0.68	Standard Deviation 1.40	cm/s
Neurovascular Coupling	Dasatinib and Quercetin	Week 8	0.26	Standard Deviation 2.04	cm/s
Neurovascular Coupling	Dasatinib and Quercetin	Week 14	0.80	Standard Deviation 2.13	cm/s
Executive Function	Dasatinib and Quercetin	Baseline (Week 2)	80.6	Standard Deviation 80.2	seconds
Executive Function	Dasatinib and Quercetin	Week 8	75.0	Standard Deviation 61.4	seconds
Executive Function	Dasatinib and Quercetin	Week 14	63.4	Standard Deviation 44.6	seconds
Gait Speed	Dasatinib and Quercetin	Baseline (Week 2)	0.87	Standard Deviation 0.15	meters/second
Gait Speed	Dasatinib and Quercetin	Week 8	0.85	Standard Deviation 0.16	meters/second
Gait Speed	Dasatinib and Quercetin	Week 14	0.87	Standard Deviation 0.14	meters/second
Montreal Cognitive Assessment (MoCA) Score	Arm 1	Baseline	23	Standard Deviation 2	points

1 to 10 of 32Source ClinicalTrials.gov

See all 32 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Dasatinib and Quercetin	15
Overall Study	COMPLETED	Dasatinib and Quercetin	12
Overall Study	NOT COMPLETED	Dasatinib and Quercetin	3

Source ClinicalTrials.gov

Adverse events37

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	General disorders	Dasatinib and Quercetin	4	15	5
other	Producing more urine than usual	Renal and urinary disorders	Dasatinib and Quercetin	1	15	1
other	Bruising	Injury, poisoning and procedural complications	Dasatinib and Quercetin	3	15	4
other	High Glucose	Metabolism and nutrition disorders	Dasatinib and Quercetin	2	15	3
other	Low White Blood Cell Count	Blood and lymphatic system disorders	Dasatinib and Quercetin	3	15	6
other	High Cystatin C Value	Renal and urinary disorders	Dasatinib and Quercetin	1	15	1
other	Irregular Glomerular Filtration Rate	Renal and urinary disorders	Dasatinib and Quercetin	1	15	2
other	Ankle Edema	General disorders	Dasatinib and Quercetin	1	15	1
other	Basilar Rales	Respiratory, thoracic and mediastinal disorders	Dasatinib and Quercetin	1	15	1
other	Irregular Heart Beat	Cardiac disorders	Dasatinib and Quercetin	1	15	1

1 to 10 of 37Source ClinicalTrials.gov

See all 37 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dasatinib and Quercetin	0	15
Total, other adverse events	Dasatinib and Quercetin	12	15
Total, serious adverse events	Dasatinib and Quercetin	1	15

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
40248131	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests2

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
1-Back Task	Primary outcome	ConductCognition
2-Back Task	Primary outcome	ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05422885

GET https://conductscience.org/api/trials/v1/NCT05422885/results?page=2

API reference For AI assistants